在与癌症这场残酷的战斗中，医学科研人员们一直在努力寻找更有效的“秘密武器”。T细胞受体工程化T细胞（TCR-T）疗法是近年来涌现出的一种极具潜力的新型癌症治疗方法。今天，咱们就一起来揭开它神秘的面纱。

不知不觉中，免疫疗法已经占据了癌症治疗版图的“半壁江山”。从免疫检查点抑制剂到CAR-T细胞疗法，人类对抗癌症的武器正在不断进步。随着CAR-T细胞疗法在血液肿瘤领域“高歌猛进”时，科学家们将目光投向了更具挑战性的实体肿瘤战场。

为解决嵌合抗原受体（CAR）T 细胞免疫疗法在实体瘤治疗中特异性差的问题，研究人员开展了共表达 T 细胞受体（TCR）和 CAR 对 CAR-T 细胞影响的研究。结果显示，经工程化的双受体 T 细胞抗癌活性更强、对健康组织毒性更小，为精准癌症免疫疗法设计提供了新方向。

Motorsport Ireland's Young Driver of The Year Max Hart today announced his plans for the 2025 season.

5 (4) A CAR controlled remotely via drugs and other small molecules puts the brakes on T cell activation and prevents exhaustion. 6,7 (5) The T cell receptor (TCR) is a protein complex that recognizes ...

Max Hart will race in the TCR Europe in 2025 after inking a deal to join forces with the returning Target Competition team. Hart will continue to compete at ...

TCR Touring Cars have had a troubled time in Australia, limited to small grids and poor attendance and viewing figures. The series debuted in 2019 as a part of the Shannons National Series ...

The Mk7 Volkswagen Golf GTI wasn’t long for this world when the GTI TCR (Touring Car Racing) came along, with the final GTIs being short-run specials. As we were driving the Golf GTI TCR ...

Last week, I had the privilege of heading into town in Boston to attend three days of the CAR-TCR conference, a major annual gathering of researchers and industry stakeholders concerned with ...